Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04720690
Other study ID # 20QC6217
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 1, 2020
Est. completion date December 2023

Study information

Verified date January 2021
Source Imperial College Healthcare NHS Trust
Contact Jayanta Banerjee, MD (Res), FRCPCH
Phone 020 3313 7308
Email j.banerjee@imperial.ac.uk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Babies may be born appropriately grown for gestational age (AGA, >10th centile) or small for gestational age (SGA, <10th centile). Babies who are SGA and have evidence in utero of vascular compromise using antenatal doppler indices are classified as having fetal growth restriction (FGR). Babies with FGR are at increased risk of cardiovascular disease in adult life. Increased arterial stiffness and intima-media thickness are thought to mediate this risk in adults. It is not known how early in life these changes can be robustly detected. In addition, very little is known generally about how babies' hearts and arteries change in structure and function over the first year of life, whether affected by SGA or not. This study aims to understand if there are differences in cardiac and arterial structure and function between babies born AGA or SGA. Within the group of SGA babies, the study team will investigate whether FGR and maternal pre-eclampsia influence these measurements. The effects gestational age on these parameters will be studied within all groups: half of the babies recruited will be <32 weeks gestational age (GA), and half will be ≥32 weeks GA. Study participants will have further measurements at 3-6 months of life to assess if cardiac and arterial structure and function change in babies over the first year of life. The study team will use the Vicorder device to measure arterial stiffness, and assess the feasibility of using this device in neonates. The Vicorder will also be used to measure cardiac output. The feasibility and validity of this device for this purpose will be investigated (Vicorder is not validated for cardiac output measurement in infants). Vicorder cardiac output results will be compared to echocardiography and bioimpedence technology (using the NICaS monitor). The study team will use ultrasound for arterial structure measurements of the carotid artery and aorta.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date December 2023
Est. primary completion date December 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A to 6 Months
Eligibility Inclusion Criteria: - Healthy term infants (including those with SGA+/-FGR) in the postnatal ward - Term and Preterm infants (including those with SGA+/-FGR) admitted to the neonatal unit - Written informed parental consent Exclusion Criteria: - Antenatal or postnatal diagnosis of complex/life-limiting congenital anomaly or genetic condition - Infants with no realistic chance of survival - Infants with fragile skin not permitting use of cuffs for research purposes - Babies whose parents have a limited understanding of English will be excluded in the event that communication via NHS translation services is not possible due to clinical demands on these services

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Vicorder: pulse wave velocity, pulse wave analysis, stroke volume, cardiac output
Measurement of arterial stiffness and cardiac output
NICaS
Measurement of cardiac output
Echocardiography and ultrasound of arteries
Measurement of cardiac output; measurement of intima-media thickness of arteries

Locations

Country Name City State
United Kingdom Queen Charlotte's and Chelsea Hospital London
United Kingdom St Mary's Hospital London

Sponsors (1)

Lead Sponsor Collaborator
Imperial College Healthcare NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of arterial and cardiac function measurements: the proportion of babies from whom study measurements are successfully obtained. Feasibility of arterial and cardiac function measurements assessed through establishing from what proportion of babies the team is able to successfully obtain these measurements. 3 years
Secondary Non-invasive measurement of arterial stiffness: brachial-femoral pulse wave velocity Brachial-femoral pulse wave velocity in metres per second (m/s) will be measured using the Vicorder and compared between neonates of different gestational age and birth weight groups at or near term corrected gestational age, and at 3-6 months of age. 3 years
Secondary Non-invasive measurement of arterial stiffness: augmentation index Augmentation index (%) will be measured using the Vicorder and compared between neonates of different gestational age and birth weight groups at or near term corrected gestational age, and at 3-6 months of age. 3 years
Secondary Arterial structure measurements The intima-media thickness of the carotid artery and abdominal aorta will be measured in micrometres (µm) using ultrasound at or near term corrected gestational age, and at 3-6 months of age. Gestational age and birth weight groups will be compared at each time point. 3 years
Secondary Cardiac output measurements: comparison of neonatal and infant birth weight and gestational age cohorts Cardiac output in L/min and ml/min/kg will be measured using echocardiography, the NICaS monitor and the Vicorder. Values obtained in different gestational age and birth weight groups will be compared at or near term corrected gestational age and at 3-6 months of age. 3 years
Secondary Cardiac output measurements: comparison of devices Cardiac output values in L/min and ml/min/kg obtained by each device (echocardiography, NICaS monitor and Vicorder) will be compared using correlation and Bland-Altman statistics. 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT03299777 - Correlation Between Changes in Liver Stiffness and Preeclampsia as Shown by Fibroscan N/A
Completed NCT03650790 - C1q/TNF-related Protein 9 (CTRP 9) Level in Preeclamptic Obese and Non-obese Pregnancies N/A
Recruiting NCT03605511 - TTP and aHUS in Complicated Pregnancies
Not yet recruiting NCT03302260 - Identifying Methods for Postpartum Reduction of Vascular Events: Pilot Randomized Controlled Trial N/A
Completed NCT02911701 - Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features Phase 4
Completed NCT01911494 - Community Level Interventions for Pre-eclampsia N/A
Terminated NCT02025426 - Phenylephrine Versus Ephedrine in Pre-eclampsia Phase 4
Completed NCT01352234 - Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia Phase 4
Active, not recruiting NCT02031393 - Establishing First Trimester Markers for the Identification of High Risk Twin N/A
Terminated NCT00141310 - Sildenafil Citrate for the Treatment of Established Pre-Eclampsia Phase 2
Completed NCT00157521 - L-Arginine in Pre-Eclampsia Phase 3
Completed NCT04795154 - Prenatal Yoga as Complementary Therapy of Preeclampsia N/A
Completed NCT00004399 - Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia N/A
Completed NCT00005207 - Renin and Prorenin in Pregnancy N/A
Recruiting NCT04551807 - Natural Versus Programmed Frozen Embryo Transfer (NatPro) Phase 3
Terminated NCT04092829 - Impact of Corpus Luteum Presence or Absence in the Incidence of Preeclampsia After Frozen Embryo Transfer N/A
Recruiting NCT06067906 - Weight Loss Following an Episode of Pre-eclampsia Using a Dissociated or Hypocaloric Diet in Overweight or Obese Patients N/A
Recruiting NCT06317467 - Role of Anti-C1q Autoantibodies in Pregnancy
Completed NCT02218931 - ESTEEM - Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes N/A
Active, not recruiting NCT04484766 - Preeclampsia Associated Vascular Aging